United States - English - NLM (National Library of Medicine)

american health packaging - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. limitations of use: - the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data). the apr uses the macdp as the u.s. reference population for birth defects in the general populatio

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. limitations of use: - the dosage of this product is for hiv-1 and not for hbv. lamivudine is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263. risk summary available data from the antiretroviral pregnancy registry show no difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% in the us reference population of the metropolitan atlanta congenital defects program (macdp). lamivudine produced embryonic toxicity in rabbits at a dose that produced similar human exposur

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - lamivudine - tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - lamivudine - tablet - 150mg

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablet is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-l) infection. limitations of use: • the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data ). the apr uses the macdp as the u.s. reference population for birth defects in the general popu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - lamivudine - tablet - 150mg

Kenya - English - Pharmacy and Poisons Board

aurobindo pharma limited p.o.box 1541-00606 nairobi - lamivudine zidovudine efavirenz - tablet - lamivudine 150 mg zidovudine 300 mg efavirenz… - antivirals for systemic use:

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

United States - English - NLM (National Library of Medicine)

apotex corp. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 100 mg - lamivudine tablets (hbv) are indicated for the treatment of chronic hepatitis b virus (hbv) infection associated with evidence of hepatitis b viral replication and active liver inflammation [see clinical studies (14.1, 14.2) ]. the following points should be considered when initiating therapy with lamivudine tablets (hbv): - due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (hbv) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. - lamivudine tablets (hbv) have not been evaluated in patients co-infected with human immunodeficiency virus (hiv), hepatitis c virus (hcv), or hepatitis delta virus. - lamivudine tablets (hbv) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis b virus infection with decompensated liver disease. lamivudine tablets (hbv) are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no substantial difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% reported in the u.s. reference population of the metropolitan atlanta congenital defects program (macdp). the apr uses the macdp as a u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occur at less than 20 weeks’ gestation. of over 12,900 women exposed to lamivudine in the apr, less than 2% were hbv mono-infected. the majority of women exposed to lamivudine in the apr were hiv-1-infected and were treated with higher doses of lamivudine compared with hbv mono-infected women. in addition to lamivudine, hiv-1-infected women were also treated with other concomitant medications for hiv-1 infection [see data]. the estimated rate of miscarriage for women exposed to lamivudine in the indicated population is unknown. the estimated background rate of miscarriage in clinically recognized pregnancies in the u.s. general population is 15% to 20%. oral administration of lamivudine to pregnant rabbits during organogenesis resulted in embryolethality at systemic exposure (auc) similar to the recommended clinical dose; however, no adverse developmental effects were observed with oral administration of lamivudine to pregnant rats during organogenesis at plasma concentrations (cmax ) 60 times the recommended clinical dose [see data] . data human data based on prospective reports from the apr of over 12,900 exposures to lamivudine during pregnancy resulting in live births (including over 5,400 exposed in the first trimester and over 7,500 exposed in the second/third trimester), there was no difference between the overall risk of birth defects with lamivudine compared with the background birth defect rate of 2.7% observed in the u.s. reference population of the macdp.the prevalence of birth defects in live births was 3.1% (95% ci: 2.7% to 3.6%) following first trimester exposure to lamivudine-containing regimens and 2.9% (95% ci: 2.5% to 3.3%) following second/third trimester exposure to lamivudine-containing regimens. the pharmacokinetics of lamivudine in patients with hbv or hiv-1 infection and in healthy volunteers are similar at similar doses. lamivudine pharmacokinetics were studied in pregnant women with hiv-1 infection during 2 clinical trials conducted in south africa. the trials assessed pharmacokinetics in 16 women at 36 weeks gestation using 150 mg lamivudine twice daily (3 times the recommended daily dosage for hbv) with zidovudine, 10 women at 38 weeks gestation using 150 mg lamivudine twice daily (3 times the recommended daily dosage for hbv) with zidovudine, and 10 women at 38 weeks gestation using lamivudine 300 mg twice daily (6 times the recommended daily dosage for hbv) without other antiretrovirals. lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples. in a subset of subjects, amniotic fluid specimens were collected following natural rupture of membranes and confirmed that lamivudine crosses the placenta in humans. based on limited data at delivery, median (range) amniotic fluid concentrations of lamivudine were 3.9- (1.2- to 12.8-) fold greater compared with paired maternal serum concentrations (n = 8). animal data lamivudine was administered orally to pregnant rats (at 90, 600, and 4,000 mg per kg per day) and rabbits (at 90, 300, and 1,000 mg per kg per day and at 15, 40, and 90 mg per kg per day) during organogenesis (on gestation days 7 through 16 [rat] and 8 through 20 [rabbit]). no evidence of fetal malformations due to lamivudine was observed in rats and rabbits at doses producing plasma concentrations (cmax ) approximately 53 or more times higher than human exposure at the recommended daily dose. evidence of early embryolethality in the absence of maternal toxicity was seen in the rabbit at systemic exposures (auc) similar to those observed in humans, but there was no indication of this effect in the rat at plasma concentrations (cmax ) 60 times higher than human exposure at the recommended daily dose. studies in pregnant rats showed that lamivudine is transferred to the fetus through the placenta. in the fertility/pre­- and postnatal development study in rats, lamivudine was administered orally at doses of 180, 900, and 4,000 mg per kg per day (from prior to mating through postnatal day 20). in the study, development of the offspring, including fertility and reproductive performance, was not affected by maternal administration of lamivudine at plasma concentrations (cmax ) 104 times higher than human exposure. risk summary lamivudine is present in human milk. there is no information available regarding lamivudine concentrations in milk from lactating women receiving lamivudine for treatment of hbv infection. however, in lactating women with hiv-1 infection being treated with lamivudine at 3 or 6 times the recommended daily dose for hbv, lamivudine concentrations in milk were similar to those observed in serum [see data]. the lamivudine dose received by a breastfed infant of a mother being treated for hiv-1 infection was estimated to be approximately 6% of the recommended daily lamivudine dose for hbv in children over 2 years of age. there is no information available regarding the effects of the drug on the breastfed infant or on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for lamivudine tablets (hbv) and any potential adverse effects on the breastfed infant from lamivudine or from the underlying maternal condition. data in mothers with hiv receiving lamivudine monotherapy (300 mg twice daily [6 times the recommended daily dosage for hbv]) or combination therapy (150 mg lamivudine twice daily [3 times the recommended daily dosage for hbv] with 300 mg zidovudine twice daily), the median breast milk to plasma lamivudine concentration ratio was 0.6 to 3.3, and the estimated infant daily dose was approximately 6% of the recommended 3-mg-per-kg daily lamivudine dose for treatment of hbv in children over 2 years of age. in breastfed infants of mothers with hiv-1 infection receiving lamivudine therapy, the blood concentrations of lamivudine decreased after delivery and were undetectable at 6 months despite constant milk concentrations. this is consistent with increased lamivudine renal clearance in the first 6 months of life. lamivudine tablets (hbv) is indicated for the treatment of chronic hepatitis b virus infection in pediatric patients aged 2 to 17 years [see indications and usage (1) , clinical pharmacology (12.3) , clinical studies (14.2) ]. the safety and efficacy of lamivudine tablets (hbv) in pediatric patients younger than 2 years have not been established. clinical trials of lamivudine tablets (hbv) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. in general, caution should be exercised in the administration of lamivudine tablets (hbv) in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see dosage and administration (2.4), clinical pharmacology (12.3)] . reduction of the dosage of lamivudine tablets (hbv) is recommended for patients with impaired renal function [see dosage and administration (2.4) , clinical pharmacology (12.3) ]. no dose adjustment for lamivudine is required for patients with impaired hepatic function.

United States - English - NLM (National Library of Medicine)

direct rx - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets usp, a combination of two nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of hiv-1 infection. lamivudine and zidovudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the product. 8.1 pregnancy pregnancy category c. fetal risk summary: there are no adequate and well-controlled studies of lamivudine and zidovudine in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and fetal malformations (zidovudine), and increased embryolethality (lamivudine). lamivudine and zidovudine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetu